Novadiscovery takes off with €5 Series A financingIn silico clinical trials pioneer Novadiscovery SA has raised €5m in a series A financing led by Swiss Debiopharm Innovation Fund. more ➔
Alderaan Biotechnology raise €18.5m in Series A financing Following a €1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised €18.5m in a Series A round led by Advent France Biotechnology and Medicxi. more ➔
North Sea Therapeutics raises US$40m in Series BNorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate. more ➔
Merck and 4SC collaborate in immunooncology4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Merck’s checkpoint blocker avelumab plus 4SC’s HDAC I blocker domatinostat. more ➔
Novo Holdings invest US$12m in AMR companiesMutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund. more ➔
Fighting sepsis mortality Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality. more ➔
Antabio SAS advances cystic fibrosis programme Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients more ➔
Hydrogel fights wound infection and inflammation Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds. more ➔
British diagnostics play OBD lands contract with US pharmaThe technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic … more ➔
Truffle’s BioMedTech fund filled with €250mParis-based European venture capital company Truffle Capital closed its €250m BioMedTech fund – celebrating its company building approach. more ➔
